Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding of the m olecular mechanism s res ponsib l e for c hronic myeloid leukemia transformation from chronic phase to the aggressive blast crisis remain limited. Here we present a large parallel sequencing analysis of 10 blast crisis samples and of the corresponding autologous chronic phase controls that reveals, for the first time, recurrent mutations affecting the ubiquitin-conjugating enzyme E2A gene (UBE2A, formerly RAD6A). Additional analyses on a cohort of 24 blast crisis, 41 chronic phase as well as 40 acute myeloid leukemia and 38 atypical chronic myeloid leukemia patients at onset confirmed that UBE2A mutations are specifically acquired during chronic myeloid leukemia progression, with a frequency of 16.7% in advanced phases. In vitro studies show that the mutations here described cause a decrease in UBE2A activity, leading to an impairment of myeloid differentiation in chronic myeloid leukemia cells.

Magistroni, V., Mauri, M., D'Aliberti, D., Mezzatesta, C., Crespiatico, I., Nava, M., et al. (2019). De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. HAEMATOLOGICA, 104(9), 1789-1797 [10.3324/haematol.2017.179937].

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Magistroni, V
Co-primo
;
Mauri, M
Co-primo
;
D'Aliberti, D;Crespiatico, I;Fontana, D;Sharma, N;Pirola, A;Redaelli, S;Massimino, L;Khandelwal, P;Citterio, S;Viltadi, M;Bombelli, S;Rigolio, R;Perego, R;Gambacorti Passerini, C
Co-ultimo
;
Piazza, R
Co-ultimo
2019

Abstract

Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding of the m olecular mechanism s res ponsib l e for c hronic myeloid leukemia transformation from chronic phase to the aggressive blast crisis remain limited. Here we present a large parallel sequencing analysis of 10 blast crisis samples and of the corresponding autologous chronic phase controls that reveals, for the first time, recurrent mutations affecting the ubiquitin-conjugating enzyme E2A gene (UBE2A, formerly RAD6A). Additional analyses on a cohort of 24 blast crisis, 41 chronic phase as well as 40 acute myeloid leukemia and 38 atypical chronic myeloid leukemia patients at onset confirmed that UBE2A mutations are specifically acquired during chronic myeloid leukemia progression, with a frequency of 16.7% in advanced phases. In vitro studies show that the mutations here described cause a decrease in UBE2A activity, leading to an impairment of myeloid differentiation in chronic myeloid leukemia cells.
Articolo in rivista - Articolo scientifico
Scientifica
Blast Crisis progression; Chronic Myelogenous Leukemia; Molecular Genetics
Ematologia, leucemia mieloide cronica, crisi blastica, mutazioni
English
Magistroni, V., Mauri, M., D'Aliberti, D., Mezzatesta, C., Crespiatico, I., Nava, M., et al. (2019). De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. HAEMATOLOGICA, 104(9), 1789-1797 [10.3324/haematol.2017.179937].
Magistroni, V; Mauri, M; D'Aliberti, D; Mezzatesta, C; Crespiatico, I; Nava, M; Fontana, D; Sharma, N; Parker, W; Schreiber, A; Yeung, D; Pirola, A; Redaelli, S; Massimino, L; Wang, P; Khandelwal, P; Citterio, S; Viltadi, M; Bombelli, S; Rigolio, R; Perego, R; Boultwood, J; Morotti, A; Saglio, G; Dong-Wook, K; Branford, S; Gambacorti Passerini, C; Piazza, R
File in questo prodotto:
File Dimensione Formato  
haematol.2017.179937.full.pdf

accesso aperto

Tipologia di allegato: Submitted Version (Pre-print)
Dimensione 1.68 MB
Formato Adobe PDF
1.68 MB Adobe PDF Visualizza/Apri
HAEMATOLOGICA 2019 Magistroni et al.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 1.68 MB
Formato Adobe PDF
1.68 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/230164
Citazioni
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 15
Social impact